Nanotechnological approaches against Chagas disease

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 576-588

  Romero, Eder Lilia ^a   Morilla, Maria Jose ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Amastigotes; Chagas disease; Drug delivery; Liposomes; Nanoparticles

Indexed keywords

AMASTIGOTES; BIODISTRIBUTIONS; CAUSATIVE AGENTS; CHAGAS DISEASE; COMPLEX LIFE; DRUG DELIVERY SYSTEM; PARASITE-; PHARMACOTHERAPIES;

LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS;

DRUG DELIVERY;

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; ALLOPURINOL; AMINO BISPHOSPHONIC ACID DERIVATIVE; AMIODARONE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBODY CONJUGATE; ANTIFLAGELLATE AGENT; BENZNIDAZOLE; BISPHOSPHONIC ACID DERIVATIVE; CYANOACRYLATE DERIVATIVE; DENDRIMER; E 5700; IBANDRONIC ACID; ITRACONAZOLE; K 777; LIPOSOME; NANOPARTICLE; NANOSPHERE; NIFURTIMOX; OCTADECYLAMINE; PAMIDRONIC ACID; POLYALKYLCYANOACRYLATE; POLYMER; POSACONAZOLE; RAVUCONAZOLE; RISEDRONIC ACID; THIORIDAZINA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AVASCULAR NECROSIS; BIODEGRADABILITY; CHAGAS DISEASE; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG UPTAKE; ELECTROLYTE DISTURBANCE; ENCAPSULATION; EYE DISEASE; HUMAN; INFLAMMATION; JAW OSTEONECROSIS; KIDNEY FAILURE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NANOTECHNOLOGY; NEPHROTIC SYNDROME; NONHUMAN; OPSONIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

AMPHOTERICIN B; ANIMALS; CHAGAS DISEASE; CHEMISTRY, PHARMACEUTICAL; DEVELOPING COUNTRIES; DRUG DELIVERY SYSTEMS; HEART; HUMANS; LACTIC ACID; LIPOSOMES; MICROSPHERES; NANOPARTICLES; NANOTECHNOLOGY; NITROIMIDAZOLES; POLYGLYCOLIC ACID; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 76849097220     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.025     Document Type: Review

References (152)

1. Organizacion Panamericana de la Salud, Estimacion cuantitativa de la enfermedad de Chagas en las Americas, Montevideo, Uruguay, OPS/HDM/CD/425 (2006).
2. WHO. The World Health Organization report 2004. Changing History (2004)
3. Strosberg A.M., Barrio K., Stinger V.H., Tashker J., Wilbur J.C., Wilson L., and Woo K. Chagas disease: a Latin American nemesis (2007)
4. Morel C.M. Reaching maturity-25 years of the TDR. Parasitol. Today 16 (2000) 522-525
5. WHO. Chagas Disease. Tropical Disease Research: Progress 1995-1996 (1997)
6. Levi G.C., Amato V., Neto J.F., and Araujo D. Analise de manisfestacoes colaterais devidas ao uso do medicamento Ro-7-1051 nitromidazolico especico da doenca de Chagas. Rev. Inst. Med. Trop. Sao Paulo 17 (1975) 49-52
7. de Andrade A.L., Zicker F., de Oliveira R.M., Almeida Silva S., Luquetti A., Travassos L.R., Almeida I.C., de Andrade S.S., de Andrade J.G., and Martelli C.M. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348 (1996) 1407-1413
8. Sosa Estani S., Segura E.L., Ruiz A.M., Velazquez E., Porcel B.M., and Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am. J. Trop. Med. Hyg. 59 (1998) 526-529
9. Cançado J.R. Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz 94 (1999) 331-336
10. Sosa Estani S., and Segura E.L. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines in Argentina. Mem. Inst. Oswaldo Cruz 94 (1999) 363-365
11. Murta S., Gazzinelli R., Brener Z., and Romanha A. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol. 93 (1998) 203-214
12. Urbina J.A., and Docampo R. Specific Chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19 (2003) 495-501
13. Chagas C. Nova trypanozomiase humana: estudos sobre morfología e o ciclo evolutivo do Schizotrypanum cruzi. Mem. Inst. Oswaldo Cruz 1 (1909) 159-221
14. Bestetti R.B., Martins C.A., and Cardinalli-Neto A. Justice where justice is due: A posthumous Nobel Prize to Carlos Chagas (1879-1934), the discoverer of American Trypanosomiasis (Chagas ́disease). Int. J. Cardiology 134 (2009) 9-16
15. DNDi.
16. Beyrer C., Villar J.C., Suwanvanichkij V., Singh S., Baral S., and Mills E.J. Neglected diseases, civil conflicts, and the right to health. Lancet 370 (2006) 619-627
17. Trouiller P., Olliaro P., Torreele E., Orbinski J., Laing R., and Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359 (2002) 2188-2194
18. http://www.dndi.org.
19. http://www.mmv.org/pages/page_main.htm.
20. http://www.oneworldhealth.org.
21. http://www.who.int/tdr/.
22. http://www.azonano.com/oars.asp.
23. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem. Inst. Oswaldo Cruz 98 (2003) 577-591
24. Leiby D.A., Herron J.R.M., Read E.J., Lenes B.A., and Stumpf R.J. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 42 (2002) 549-555
25. Leiby D.A., Herron R.M.J., Garratty G., and Herwaldt B.L. Trypanosoma cruzi parasitemia in US blood donors with serologic evidence of infection. J. Infect. Dis. 198 (2008) 609-613
26. Beard C.B., Pye G., Steurer F.J., Rodriguez R., Campman R., and Peterson A.T. Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg. Infect. Dis. 9 (2003) 103-105
27. Diaz J.H. Recognizing and reducing the risks of Chagas disease (American trypanosomiasis) in travellers. J. Travel. Med. 15 (2008) 184-195
28. Lescure F.X., Canestri A., Melliez H., Jauréguiberry S., Develoux M., Dorent R., Guiard-Schmid J.B., Bonnard P., Ajana F., Rolla V., Carlier Y., Gay F., Elghouzzi M.E., Danis M., and Pialoux G. Chagas disease, France. Emerg. Infect. Dis. 14 (2008) 644-646
29. Rodriguez-Morales A.J., Rivas M.A., and Benitez J.A. Chagas Disease: a neglected cardiomyopathy. Heart-electronic letters (2008)
30. Cordova E., Boschi A., Ambrosioni J., Cudos C., and Corti M. Reactivation of Chagas' disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int. J. Infect. Dis. 12 (2008) 587-592
31. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 2 (2001) 92-100
32. Cuellar M., Salas C., Cortes M., Morello A., Maya J., and Preite M. Synthesis and in vitro trypanocide activity of several polycyclic drimanequinone derivatives. Bioorg. Med. Chem. 11 (2003) 2489-2497
33. Bustamante J.M., Lo Presti M.S., Rivarola H.W., Fernández A.R., Enders J.E., Fretes R.E., and Paglini-Oliva P. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas' disease improves cardiopathy. Int. J. Antimicrob. Agents 29 (2007) 733-737
34. Croft S.L., Barrett M.P., and Urbina J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 21 (2005) 508-512
35. Buckner F.S., Griffin J.H., Wilson A.J., and Van Voorhis W.C. Potent anti-Trypanosma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother. 45 (2001) 1210-1215
36. Du X., Guo C., Hansell E., Doyle P.S., Caffrey C.R., Holler T.P., and McKerrow J.H. C. F.E., Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. 45 (2002) 2695-2707
37. Urbina J.A., Concepcion J.L., Caldera A., Payares G., Sanoja C., Otomo T., and Hiyoshi H. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother. 48 (2004) 2379-2387
38. http://www.oneworldhealth.org/diseases/chagas.php.
39. Urbina J.A., Payares G., Sanoja A., Lira R., and Romanha A. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 21 (2003) 27-38
40. Rassi Jr. A., Rassi G.G., Rassi S.G., Garcia Da Silva I., and Rassi A.G. Lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am. J. Trop. Med. Hyg. 76 (2007) 58-61
41. Rivarola H.W., Fernandez A.R., Enders J.E., Fretes R., Gea S., Suligov M., Palma J.A., and Paglini-Oliva P.A. Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice. Ann. Trop. Med. Parasitol. 93 (1999) 695-702
42. Lo Presti M.S., Rivarola H.W., Bustamante J.M., Fernandez A.R., Enders J.E., Fretes R., Gea S., and Paglini-Oliva P.A. Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice. Int. J. Antimicrob. Agents 23 (2004) 634-636
43. Guedes P.M., Urbina J.A., de Lana M., Afonso L.C., Veloso V.M., Tafuri W.L., Machado-Coelho G.L., Chiari E., and Bahia M.T. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother. 48 (2004) 4286-4292
44. J.A. Urbina, Product Development (Preclinical And Clinical) Research Of New Therapeutic Tools For The Specific Treatment Of Chagas Disease, (2005-revisted 2007) 16.
45. Assael L.A. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: Clinical findings, assessment of risks, and preventive strategies. J. Oral Maxillofac. Surg. 67 (2009) 35-43
46. Scott D.A., Docampo R., Dvorak J.A., Shi S., and Leapman R. In situ compositional analysis of acidocalcisomes in Trypanosoma cruzi. J. Biol. Chem. 272 (1997) 28020-28029
47. Scott D.A., de Souza W., Benchimol M., Zhong L., Lu H.G., Moreno S.N.J., and Docampo R. Presence of a plant-like proton-pumping pyrophosphatase in acidocalcisomes of Trypanosoma cruzi. J. Biol. Chem. 273 (1998) 22151-22158
48. Martin M.B., Grimley J.S., Lewis J.C., Heath H.T., Bailey B.N., Kendrick H., Yardley V., Caldera A., Lira R., Urbina J.A., Moreno S.N.J., Docampo R., Croft S.L., and Oldfield E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy. J. Med. Chem. 44 (2001) 909-916
49. Urbina J.A., Moreno B., Oldfield S.V.E., Payares G., Sanoja C., Bailey B.N., Yan W., Scott D.A., Moreno S.N.J., and Docampo R. Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J. Biol. Chem. 274 (1999) 33609-33615
50. Garzoni L.R., Waghabi M.C., Baptista M.M., de Castro S.L., Meirelles M.N.L., Britto C., Docampo R., Oldfield E., and Urbina J.A. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int. J. Antimicrob. Agents 23 (2004) 286-290
51. Bouzahzah B., Jelicks L.A., Morris S.A., Weiss L.M., and Tanowitz H.B. Risedronate in the treatment of Murine Chagas' disease. Parasitol. Res. 96 (2005) 184-187
52. Cremers S.C.L.M., Pillai G., and Papapoulos S.E. Pharmacokinetics/ pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clin. Pharmacol. 44 (2005) 551-570
53. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. (2006) 508-514
54. Tanvetyanon T., and Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. 17 (2006) 897-907
55. Fantasia J.E. Bisphosphonates-what the dentist needs to know: Practical considerations. J. Oral Maxillofac. Surg. 67 (2009) 53-60
56. Szajnman S.H., Bailey B.N., Docampo R., and Rodriguez J.B. Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorg. Med. Chem. Lett. 11 (2001) 789-792
57. www.fda.gov/nanotechnology/faqs.html.
58. Oberdörster G., Oberdörster E., and Oberdörster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113 (2005) 823-839
59. NIH (National Institutes of Health)/NCI (National Cancer Institute) Cancer Nanotechnology Plan.
60. Duncan R. Targeting and intracellular delivery of drugs. In: Meyers R.A. (Ed). Encyclopedia of Molecular Cell Biology and Molecular Medicine (2005), Weinheim, Wiley-VCH Verlag 163-204
61. Allen T.M. Adventures in targeting. Nat. Rev. Drug Discov. 2 (2002) 750-763
62. Damle N.K., and Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Phamacol. 3 (2003) 386-390
63. Milenic D.E., Brady E.D., and Brechbiel M.W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. 3 (2004) 488-498
64. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
65. O'Shaughnessy J.A., Blum J.L., Sandbach J.F., Savin M.A., Fenske E., Hawkins M.J., and Baylor-Charles A. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Proc. San Antonio Breast Cancer Symp. (2004) 1070
66. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
67. Faraji A.H., and Wipf P. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 17 (2009) 2950-2962
68. Sosnik A., Chiappetta D.A., and Carcaboso M.A. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. J Control. Rel. 38 (2009) 2-15
69. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn?. Int. J. Antimicrob. Agents 34 (2009) 15-20
70. Kao H.P., Abney J.R., and Verkmann A.S. Determinants of the translational mobility of a small solute in cell cytoplasm. J. Cell Biol. 120 (1993) 175-184
71. Belting M., Sandgren S., and Wittrup A. Nuclear delivery of macromolecules: barriers and carriers. Adv. Drug Del. Rev. 57 (2005) 505-527
72. Prokop A., and Davidson J.M. Nanovehicular intracellular delivery systems. J. Pharm. Sci. 97 (2008) 3518-3590
73. Hussain N., Jaitley V., and Florence A.T. Recent advances in the understanding of uptake of microparticles across the gastrointestinal lymphatics. Adv. Drug Del. Rev. 50 (2001) 107-142
74. Brayden D.J., Jepson M.A., and Baird A.W. Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Del. Tech. 10 (2005) 1145-1157
75. Jevprasesphant R., Penny J., Attwood D., McKeown N.B., and D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 20 (2003) 1543-1550
76. Jevprasesphant R., Penny J., Attwood D., and D'Emanuele A. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J. Controll. Rel. 97 (2004) 259-226
77. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopham. 71 (2009) 445-462
78. Alderson N.E. Interview is special FDA regulation of nanomedicine needed?. Health Aff. 27 (2008) w315-w317
79. Alonso M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58 (2004) 168-172
80. Conner S.D., and Schmid S.L. Regulated portals of entry into the cell. Nature 422 (2003) 37-44
81. Di Marzio L., Marianecci C., Cinque B., Nazzarri M., Cimini A.M., Cristiano L., Cifone M.G., Alhaique F., and Carafa M. pH-sensitive non-phospholipid vesicle and macrophage-like cells: Binding, uptake and endocytotic pathway. Biochim. Biophys. Acta 1778 (2008) 2749-2756
82. de Souza W., Narcisa C.S.A., and Silva L.C. Electron microscopy and cytochemistry analysis of the endocytic pathway of pathogenic protozoa. Prog. Histochem. Cytochem. 44 (2009) 67-124
83. Yoshihara E., Tachaban H., and Nakae T. Trypanocidal activity of the stearylamine -bearing liposome. Life Sci. 40 (1987) 2153-2159
84. de Souza W., Arguello C., Martinez-Palomo A., Trissl D., Gonzalez-Robles A., and Chiari E. Surface charge of Trypanosoma cruzi. Binding of cationized ferritin and measurement of cellular electrophoretic mobility. J. Protozool. 24 (1977) 411-415
85. Souto-Padron T., de Carvalho T.U., Chiari E., and de Souza W. Further studies on the cell surface charge of Trypanosoma cruzi. Acta Trop. 41 (1984) 215-225
86. de Carvalho T.U., Souto-Padron T., and de Souza W. Trypanosoma cruzi: surface charge and freeze-fracture of amastigotes. Exp. Parasitol. 59 (1985) 12-23
87. Gonzalez-Martin G., Merino I., Rodriguez-Cabezas M.N., Torres M., Nuñez R., and Osuna A. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. J. Pharm. Pharmacol. 50 (1998) 29-35
88. Sánchez G., Cuellar D., Zulantay I., Gajardo M., and González-Martin G. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol. Res. 35 (2002) 39-45
89. Gonzalez-Martín G., Figueroa C., Merino I., and Osuna A. Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur. J. Pharm. Biopharm. 49 (2000) 137-142
90. Scherer D., Robinson J.R., and Kreuter J. Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 101 (1994) 165-168
91. Leonard F., Kulkarni R.K., Brandes G., Nelson J., and Cameron J.J. Synthesis and degradation of poly(alkyl a-cyanoacrylates). J. Appl. Polym. Sci. 10 (1996) 259-272
92. Molina J., Urbina J.A., Gref R., Brener Z., and Maciel Rodrigues J.J. Cure of experimental Chagas ́s disease by the bis-triazole D0870 incorporated into stealth polyethyleneglycol-polylactide nanospheres. J. Antimicrob. Chemother. 47 (2001) 101-104
93. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V.P., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
94. Molina J., Brener Z., Romanha A., and Urbina J.A. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J. Antimicrob. Chemother. 46 (2000) 137-140
95. McCabe R.E. Failure of ketoconazole to cure chronic murine Chagas disease. J. Infect. Dis. 158 (1988) 1408-1409
96. Moreira A.A.B., De Souza H.B.W.T., Amato Neto V., Matsubara L., Pinto P.L., Tolezano J.E., Nunes E.V., and Okumura M. Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi. Rev. Inst. Méd. Trop. Sao Paulo 34 (1992) 177-180
97. Brener Z., Cançado J.R., Galvä L.M., Luz Z.M.P., Filardi L.S., Pereira M.C.S., Santos L.M.T., and Cancado C.B. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz 88 (1993) 149-153
98. Ritter W. Pharmacokinetics of azole compounds. In: Berg D., and Pempel M. (Eds). Sterol biosynthesis inhibitors (1988), Ellis Horwood Ltd, Chichester 397-429
99. Urbina J.A. Specific treatment of Chagas disease: current status and new developments. Curr. Opin. Infect. Dis. 14 (2001) 733-741
100. Urbina J.A. Chemotherapy of Chagas disease. Curr. Pharm. Des. 8 (2002) 287-295
101. Williams K.J., and Denning D.W. Termination of development of D0870. J. Antimicrob. Chemother. 47 (2001) 720-721
102. Yardley V., and Croft S.L. In vitro and in vivo activity of amphotericin b-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg. 61 (1999) 193-197
103. Horvath A.E., and Zierdt C.H. The effect of amphotericin B on Trypanosoma cruzi in vitro and in vivo. J. Trop. Med. Hyg. 77 (1974) 144-149
104. de Castro S.L. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop. 53 (1993) 83-98
105. Morilla M.J., Benavidez P., Lope M.O., Bakas L., and Romero E.L. Development and in vitro characterisation of a benznidazole liposomal formulation. Int. J. Pharm. 249 (2002) 89-99
106. Morilla M.J., Montanari J.A., Prieto M.J., Lopez M.O., Petray P.B., and Romero E.L. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. Int. J. Pharm. 278 (2004) 311-318
107. Morilla M.J., Montanari J., Frank F., Malchiodi E., Corral R., Petray P., and Romero E.L. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. J. Controll. Rel. 103 (2005) 599-607
108. Petray P.B., Morilla M.J., Corral R.S., and Romero E.L. In vitro activity of etanidazole against the protozoan parasite Trypanosoma cruzi. Mem. Inst. Oswaldo Cruz 99 (2004) 233-235
109. Rosenbaum M.B. Chagasic myocardiopathy. Prog. Cardiovasc. Dis. 7 (1964) 199-225
110. Leon J.S., and Engman D.M. The significance of autoimmunity in the pathogenesis of Chagas heart disease. Front. Biosci. 8 (2003) 315-322
111. Soares M.B.P., Silva-Mota K.N., Lima R.S., Bellintani M.C., Pontesde- Carvalho L., and Ribeiro-dos-Santos R. Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. Am. J. Pathol. 159 (2001) 703-709
112. Reilly J.P., Grise M.A., Fortuin F.D., Vale P.R., Schaer G.L., Lopez J., van Camp J.R., Henry T., Richenbacher W.E., Losordo D.W., Schatz R.A., and Isner J.M. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of vegf-2 in no-option patients. J. Interv. Cardiol. 18 (2005) 27-31
113. Azuma J., Taniyama Y., Takeya Y., Iekushi K., Aoki M., Dosaka N., Matsumoto K., Nakamura T., Ogihara T., and Morishita R. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther. 13 (2006) 1206-1213
114. Choi J.S., Kim K.B., Han W., Kim D.S., Park J.S., Lee J.J., and Lee D.S. Efficacy of therapeutic angiogenesis by intramyocardial injection of pckvegf165 in pigs. Ann. Thorac. Surg. 82 (2006) 679-686
115. Mayer C.R., and Bekeredjian R. Ultrasonic gene and drug delivery to the cardiovascular system. Adv. Drug Del. Rev. 60 (2008) 1177-1192
116. Skyba D.M., Price R.J., Linka A.Z., Skalak T.C., and Kaul S. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation 98 (1998) 290-293
117. Shohet R.V., Chen S., Zhou Y.T., Wang Z., Meidell R.S., Unger R.H., and Grayburn P.A. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 101 (2000) 2554-2556
118. Muller O.J., Katus H.A., and Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc. Res. 73 (2007) 453-462
119. Andrade Z.A., and Andrade S.G. The pathology of Chagas' disease (cardiac chronic form). Bol. Fund. G. Moniz 6 (1955) 1-53
120. Laranja F.S., Dias E., Nobrega G., and Miranda A. Chagas' disease: a clinical, epidemiologic and pathologic study. Circulation 14 (1956) 1035-1059
121. Ferrans V.J., Milei J., Tomiata Y., and Storino R.A. Basement membrane thickening in cardiac myocytes and capillaries in chronic Chagas' disease. Am. J. Cardiol. 61 (1988) 1137-1140
122. Vianna G. Contribuição para o estudo da anatomia patológica da moléstia de Chagas. Mem. Inst. Oswaldo Cruz 3 (1911) 276-294
123. Torres C.M. Miocitólise e fibrose do miocárdio na doença de Chagas. Mem. Inst. Oswaldo Cruz 58 (1960) 161-182
124. Morris A.S., Tanowitz H.B., Wittner M., and Bilezikian J.P. Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 82 (1990) 1900-1909
125. Rossi M.A. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am. Heart J. 120 (1990) 233-236
126. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., and Simões M.V. Pathogenesis of Chronic Chagas Heart Disease. Circulation 115 (2007) 1109-1123
127. Marin-Neto J.A., Simões M.V., Ayres-Neto E.M., Attab-Santos J.L., Gallo Jr. L., Amorim D.S., and Maciel B.C. Studies of the coronary circulation in Chagas' heart disease. São Paulo Med. J. 113 (1995) 826-834
128. Batista D.G.J., Silva C.F., Mota R.A., Costa L.C., Meirelles M.N.L., Meuser-Batista M., and Soeiro M.N.C. Trypanosoma cruzi modulates the expression of rabs and alters the endocytosis in mouse cardiomyocytes in vitro. J. Histochem. Cytochem. 54 (2006) 605-614
129. Balijepalli R.C., and Kamp T.J. Caveolae, ion channels and cardiac arrhythmias. Prog. Biophys. Mol. Biol. 98 (2008) 149-160
130. Oh P., Borgstrom P., Witkiewicz H., Li Y., Borgstrom B.J., Chrastina A., Iwata K., Zinn K.R., Baldwin R., Testa J.E., and Schnitzer J.E. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 25 (2007) 327-337
131. Griffiths P.C., Paul A., Khayat Z., Wan K.-W., King S.M., Grillo I., Schweins R., Ferruti P., Franchini J., and Duncan R. Understanding the mechanism of action of poly(amidoamine)s as endosomolytic polymers: correlation of physicochemical and biological properties. Biomacromolecules 5 (2004) 1422-1427
132. Vicent M.J., Tomlinson R., Brocchini S., and Duncan R. Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation. J. Drug Targeting 12 (2004) 491-501
133. Minchin R. Sizing up targets with nanoparticles. Nature Nanotechnology 3 (2008) 12-13
134. Wagner A., Vorauer-Uhl K., and Katinger H. Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur. J. Pharm. Biopham. 54 (2002) 213-219
135. Teeguarden J.G., Hinderliter P.M., Orr G., Thrall B.D., and Joel G. Pounds particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 95 (2007) 300-312
136. Ishida T., Ichihara M., Wang X.Y., Yamamoto K., Kimura J., Majima E., and Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsable for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 112 (2006) 15-20
137. Florence A.T. Pharmaceutical nanotechnology: More than size. Ten topics for research. Int. J. Pharm. 339 (2007) 1-2
138. Apt W., Aguilera X., Arribada A., Pérez C., Miranda C., Sánchez G., Zulantay I., Cortés P., Rodriguez J., and Juri D. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann. Trop. Med. Parasitol. 97 (2003) 23-29
139. Molina J., Martins-Filho O., Brener Z., Romanha A., Loebenberg D., and Urbina J.A. Activities of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44 (2000) 150-155
140. Urbina J.A., Payares G., Molina J., Sanoja A., Liendo A., Lazardi K., Piras M.M., Piras R., Perez N., Wincker P., and Ryley J.F. Cure of short- and long-term experimental Chagas disease using D0870. Science 273 (1996) 969-971
141. Urbina J.A., Lira R., Visbal G., and Bartroli J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44 (2000) 2498-2502
142. Urbina J.A., Payares G., Sanoja A., Molina J., Lira R., Brener Z., and Romanha A. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21 (2003) 39-48
143. Corrales M., Cardozo R., Segura M.A., Urbina J.A., and Basombrio M.A. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother. 49 (2005) 1556-1560
144. Rosenbaum M.B., Chiale P.A., Haedo A., Lazzari J.O., and Elizari M.V. Ten years of experience with amiodarone. Am. Heart J. 106 (1983) 957-964
145. Rassi Jr. A., Rassi A., and Little W.C. Chagas' heart disease. Clin. Cardiol. 23 (2000) 883-889
146. Engel J.C., Doyle P.S., Hsieh I., and McKerrow J.H. Cysteine protease inhibitors cure experimental Trypanosoma cruzi infection. J. Exp. Med. 188 (1998) 725-734
147. Garzoni L.R., Caldera A., Meirelles M.N.L., de Castro S.L., Docampo R., Meints G.A., Oldfield E., and Urbina J.A. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int. J. Antimicrob. Agents 23 (2004) 273-285
148. Docampo R., and Moreno S.N.J. Bisphosphonates as chemotherapeutic agents against Trypanosomatid and Apicomplexan parasites. Curr. Drug Target Infec. Disord. 1 (2001) 51-61
149. Stoppani A.O.M. Quimioterapia de la Enfermedad de Chagas. Medicina 59 (1999) 147-165
150. Lauria-Pires L., de Castro C.N., Emanuel A., and Prata A. Ineffectiveness of allopurinol in patients in the acute phase Chagas of Chagas disease. Rev. Soc. Bras. Med. Trop. 21 (1988) 79-80
151. Rassi A., Luquetti A.O., and Rassi J. A., G.G. Rassi, S.G. Rassi, D.A.S. IG, A.G. Rassi, Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am. J. Trop. Med. Hyg. 76 (2007) 58-61
152. Apt W., Aguilera X., Arribada A., Pérez C., Miranda C., Sánchez G., Zulantay I., Cortés P., Rodriguez J., and Juri D. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59 (1998) 133-138